Fennec Pharmaceuticals Inc.
FENC
$9.04
$0.364.15%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.91% | -65.52% | -18.59% | 7.05% | 118.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.91% | -65.52% | -18.59% | 7.05% | 118.41% |
| Cost of Revenue | 59.05% | -32.18% | -2.34% | 309.97% | 310.81% |
| Gross Profit | 30.52% | -66.25% | -19.82% | -9.17% | 109.44% |
| SG&A Expenses | -1.96% | -17.95% | -24.88% | 49.14% | 47.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.67% | -17.84% | -23.32% | 61.66% | 53.94% |
| Operating Income | 45.78% | -105.88% | 48.62% | -411.50% | -7.99% |
| Income Before Tax | 43.24% | -109.08% | 39.60% | -207.18% | -2.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.24% | -109.08% | 25.99% | -207.18% | -2.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.24% | -109.08% | 25.99% | -207.18% | -2.00% |
| EBIT | 45.78% | -105.88% | 48.62% | -411.50% | -7.99% |
| EBITDA | 46.00% | -105.41% | -- | -- | -- |
| EPS Basic | 44.00% | -108.89% | 27.70% | -198.43% | 1.17% |
| Normalized Basic EPS | 43.98% | -108.89% | 43.61% | -200.23% | 1.17% |
| EPS Diluted | 44.00% | -110.29% | 18.90% | -199.15% | 3.14% |
| Normalized Diluted EPS | 43.98% | -110.24% | 43.61% | -200.23% | 1.17% |
| Average Basic Shares Outstanding | 1.34% | 1.97% | 2.34% | 2.91% | 3.17% |
| Average Diluted Shares Outstanding | 1.34% | -11.43% | 2.34% | 2.91% | 3.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |